Key Takeaways TEM launched xM liquid biopsy to monitor ICI therapy response in solid tumors. Tempus AI introduced Loop, an AI platform combining RWD and CRISPR screens. Development of xH signals TEM's move into WGS to guide hematologic cancer treatment choice.Tempus AI (TEM) continues to push the boundaries of precision medicine through a robust pipeline of research and development (R&D) initiatives. In June, the company introduced xM, a liquid biopsy assay to detect molecular response to immune-checkpoin ...

ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) complied with federal securities laws. On May 6, 2025, Myriad Genetics reported first quarter 2025 financial results, and lowered its 2025 financial guidance, revealing, among other things, a decline in pharmacogenomics revenue by 20% year-over-year “due to UnitedHealthcare (UNH) reduc[ing] coverage of GeneSight.” Following this news, the price of ...

Key Takeaways Myriad Genetics is expanding in oncology diagnostics and prenatal testing for future growth. MYGN's GeneSight test lost UnitedHealthcare coverage, cutting related revenues by 20% year over year. Despite market pressures, MYGN posted four straight earnings beats and maintained strong solvency.Myriad Genetics, Inc. (MYGN) focuses on the expansion of companion diagnostics, market expansion through new clinical guidelines and providing new offerings in its Oncology business. The company plans to ...

Myriad Genetics (MYGN) FY Conference June 11, 2025 02:00 PM ET Speaker0 All right. Good afternoon, everyone. My name is Matt Sykes, the Life Science Tools and Diagnostics Analyst at Goldman Sachs, and I have the pleasure of welcoming Myriad Genetics to our conference this afternoon, Sam Raha, President and CEO and Scott Loeffler, CFO. Sam, Scott, thanks for joining me. Pleasure to be here. Thanks for having us. Speaker1 Thanks for having us, Matt. Speaker0 Great. Maybe, Sam, if we just start off at a high l ...

A month has gone by since the last earnings report for Myriad Genetics (MYGN) . Shares have added about 23.9% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Myriad due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Then?It turns o ...

Myriad Genetics (MYGN) FY 2025 Annual General Meeting June 05, 2025 10:00 AM ET Speaker0 Good day, and welcome to the Myriad Genetics Inc. Annual Meeting of Stockholders. I would now like to turn the conference over to Ms. Louise Van Please go ahead. Speaker1 Thank you, operator. Welcome to the twenty twenty five Annual Meeting of Stockholders of Myriad Genetics Inc. I'm Louise Fanstiel, Chair of the Board, and it is my pleasure to welcome you. It is eight a. Mountain Time, and in accordance with the notice ...

Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing Early access via large-scale clinical study to establish the validity and utility of the FirstGeneTM screen SALT LAKE CITY, June 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced early access to the FirstGeneTM Multiple Prenatal Screen. The company will begin a large study that will s ...

MONSTAR-SCREEN-3 study showed 100% detection of circulating tumor DNA (ctDNA) at baseline timepoint, and 60% of patients testing positive one month after surgery had tumor fractions only detectable via ultra-sensitive MRDSALT LAKE CITY, June 02, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced new molecular residual disease (MRD) clinical data from the MONSTAR-SCREEN 3 study, a collaboration with the National Can ...

Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaboratorsSALT LAKE CITY, May 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share data from seven new research studies at the 2025 ASCO Annual Meeting, including MRD clinical outcome data from the MONSTAR-SCREEN-3 study. Myriad will also highlight how its comprehensive portfolio of ...

文章核心观点 公司宣布管理层计划参加两场投资者医疗保健会议，可在指定网址查看直播和存档网络直播 [1] 公司信息 - 公司是分子诊断测试和精准医学领域的领先企业，致力于提升全民健康福祉 [2] - 公司开发并提供分子检测服务，可评估患病或疾病进展风险，指导跨医学专业的治疗决策，改善患者护理并降低医疗成本 [2] 会议信息 - 美银证券2025年医疗保健会议，2025年5月14日周三下午6点（更新时间）举行炉边谈话 [3] - 高盛第46届年度全球医疗保健会议，2025年6月11日周三下午2点举行炉边谈话 [3] 联系方式 - 投资者联系：Matt Scalo，电话(801) 584-3532，邮箱IR@myriad.com [3] - 媒体联系：Kate Schraml，电话(224) 875-4493，邮箱PR@myriad.com [3] 直播信息 - 所有演讲的直播和存档网络直播可在investor.myriad.com查看 [1]